Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

TNYA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Tenaya Therapeutics, Inc.NASDAQ: TNYA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $14.84M fell 29.6% year over year, behind the -24.6% change in trailing-twelve-month research & development. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at -10.1% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -29.6% toward the trailing-twelve-month pace of -24.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.84M+0.3% QoQ
Last fiscal yearDec 2025
$68.61M-20.9% YoY
LTMMar 2026
$62.37M-24.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.6%——
1 year-20.9%——
3-year CAGR-10.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
68.61M USD
Year-over-year change
-20.9%
4-year CAGR
+6.0%

Research & Development vs competitors

How TNYA compares with its peers on the latest reported figures

  • TNYA's LTM Mar 2026 research & development of $62.37M is the 9th highest of the 11 companies compared; the peer median is $80.59M.
  • Its year-over-year change of -24.6% is the 8th highest of 11, against a peer median of -12.0%.
  • Research & development amounts to 27721.8% of revenue for TNYA, versus a peer median of 411.5%.
TNYA Competitors Peer median
Research & Development for TNYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B +22061.7%+5.1%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$127.75M -3.1%+30.4%350.1%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M -28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M -33.8%+0.5%473.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M +21.5%-5.1%550.2%
HUMAHumacyte, Inc.LTM Mar 2026$73.35M -11.4%+3.1%3638.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M -24.6%-10.1%27721.8%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M -12.6%+4.1%—
ABEOAbeona Therapeutics Inc.LTM Mar 2026$26.43M -28.8%-2.5%181.7%
Peer median (excluding TNYA) $80.59M-12.0%+1.8%411.5%

Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue4.03M8.71M8.69M8.47M8.44M
Gross Profit(4.03M)(8.71M)(8.69M)(8.47M)(8.44M)
Gross Margin—————
Research & Development54.39M94.54M98.04M86.74M68.61M
Selling, General & Admin14.39M22.37M24.47M20.74M24.72M
Operating Expenses68.78M116.91M122.51M107.48M84.9M
Depreciation & Amortization4.03M8.71M8.69M8.47M8.44M
EBITDA(68.7M)(114.95M)(115.4M)(102.66M)(82.16M)
EBITDA Margin—————
Operating Income(72.81M)(125.62M)(131.19M)(115.95M)(93.33M)
Operating Margin—————
Interest Income108K1.95M7.06M4.74M2.68M
Interest Expense00000
Other Income / Expenses85K1.96M7.11M4.82M2.73M
Income Before Tax(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Net Margin—————
EPS (Basic)(1.69)(2.76)(1.68)(1.31)(0.59)
EPS (Diluted)(1.69)(2.76)(1.68)(1.31)(0.59)
Weighted Avg Shares41.29M44.82M73.79M84.82M152.97M
Weighted Avg Shares (Diluted)41.29M44.82M73.79M84.82M152.97M

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Intrinsic Alpha fair value

Locked

Current Price

$0.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.